Treatment of polycystic ovary syndrome with insulin-lowering agents

Bibliography

• HOMBURG R: Should patients with polycystic ovarian syndrome be treated with metformin? Human Reprod. (2002) 17:853–856.
   Google Scholar
• MOGHETTI P: Advances in the treatment of polycystic ovary syndrome. Expert Opin. Investig. Drugs(2001) 10:1631–1640.
   PubMed Web of Science ®Google Scholar
• LOBO RA, CARMINA E: The importance of diagnosing the polycystic ovary syndrome. Ann. Intern. Med. (2000) 132:989–993.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, WANG P, FONTAINE R, TRACY T, SIEVE-SMITH L: Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism (1999) 48:511–519.
   PubMed Web of Science ®Google Scholar
• ••Large open-label study of reversal of endocrinopathy of PCOS by metformin.
   Google Scholar
• GLUECK CJ, WANG P, FONTAINE RN, SIEVE-SMITH L, TRACY T, MOORE SK: Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism (1999) 48:1589–1595.
   PubMed Web of Science ®Google Scholar
• ••PAI-Fx, a cause of high miscarriage rate inPCOS.
   Google Scholar
• GLUECK CJ, AWADALLA SG, PHILLIPS H, CAMERON D, WANG P, FONTAINE RN: Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of M vitro fertilized embryos, and miscarriage. Fertil. Steril. (2000) 74:394–397.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, PHILLIPS H, CAMERON D et al.: Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Feral. Steril. (2001) 75:46-52. Safe, non-teratogenic reduction of first trimester SAB in PCOS with metformin.
   Google Scholar
• GLUECK CJ, WANG P, FONTAINE R, TRACY T, SIEVE-SMITH L: Metformin to restore normal menses in oligoamenorrheic teenage girls with polycystic ovary syndrome (PCOS). Ado]. Health (2001) 29:160–169.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, SIEVE-SMITH L, GOLDENBERG N et al.: Metformin improves pregnancy outcomes in 295 women (328 pregnancies) with polycystic ovary syndrome. Invest. Med. (2002) 50:163A. Abstract.
   Google Scholar
• ••Safe, non-teratogenic reduction of firsttrimester spontaneous abortion in PCOS with metformin. Largest study during pregnancy to date.
   Google Scholar
• GLUECK CJ, WANG P, KOYABASHI S et al.: Metformin therapy throughout pregnancy reduces development of gestational diabetes in women with
   Google Scholar
• •• polycystic ovary syndrome. Fen. Sten7. (2002) 77:520-525. Tenfold reduction in gestational diabetes with metformin in women with PCOS.
   Google Scholar
• CARMINA E, LOBO RA: Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. j Clin. Endocrine] Metabol (1999) 84:1897–1899.
   PubMed Web of Science ®Google Scholar
• KNOCHENHAUER ES, KEY TJ, KASHAR-MILLER M, WAGGONER W, BOOTS LR, AZZIZ R: Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin. Endocrine] Metab. (1998) 83:3078–3082.
   PubMed Web of Science ®Google Scholar
• ••Prevalence of PCOS.
   Google Scholar
• GUZICK DS: Polycystic ovary syndrome: symptomatology, pathophysiology, and epidemiology. Jim. j °Enter Gynecol (1998) 179:S89–S93.
   PubMedGoogle Scholar
• VELAZQUEZ EM, MENDOZA S, HAMER T, SOSA F, GLUECK CJ: Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism (1994) 43:647–654.
   PubMed Web of Science ®Google Scholar
• ••First study documenting reversal ofendocrinopathy of PC OS with metformin.
   Google Scholar
• FLEMING R, HOPKINSON ZE, WALLACE RE et al: Ovarian function and Metabolic factors in women with oligomenorrhea treated with metformin in a randomized double-blind, placebo-controlled trial. I Clin. Endocrine] Metab. (2002) 87:569–574.
   PubMed Web of Science ®Google Scholar
• ••Largest placebo-controlled, double-blindstudy of metformin in PCOS to date.
   Google Scholar
• CLARK AM, LEDGER W, GALLETLY C et al.: Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum. Reprod. (1995) 10:2705–2712.
   PubMed Web of Science ®Google Scholar
• KIDDY DS, HAMILTON-FAIRLEY D, BUSH A et al.: Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin. Endocrine] (Oxford) (1992) 36:105–111.
   PubMed Web of Science ®Google Scholar
• VELAZQUEZ E, ACOSTA A, MENDOZA SG: Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstet. Gynecol (1997) 90:392–395.
   PubMed Web of Science ®Google Scholar
• VELAZQUEZ EM, MENDOZA SG, WANG P, GLUECK CJ: Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism (1997) 46:454–457.
   PubMed Web of Science ®Google Scholar
• DE CONCILIS B, PASSANNANTI G, ROMANO L, SANTARPIA R: Effects of metformin on the insulin resistance and on ovarian steroidogenesis in women with polycystic ovary syndrome. Minerva Ginecol (2001) 53:239–250.
   PubMedGoogle Scholar
• IBANEZ L, VALLS C, POTAU N, MARCOS MV, DE ZEGHER F: Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. Clin. Endocrine] Metab. (2000) 85:3526–3530.
   PubMed Web of Science ®Google Scholar
• KOIVUNEN RIVI, MORIN-PAPUNEN LC, RUOKONEN A, TAPANAINEN JS, MARTIKAINEN HK: Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin. Hum. Reprod. (2001) 16:2546–2551.
   PubMedGoogle Scholar
• KOLODZIEJCZYK B, DULEBA AJ, SPACZYNSKI RZ, PAWELCZYK L: Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fern] Sterd. (2000) 73:1149–1154.
   PubMed Web of Science ®Google Scholar
• LA MARCA A, MORGANTE G, PAGLIA T, CIOTTA L, CIANCI A, DE LEO V: Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. Fern] Sterd. (1999) 72:985–989.
   PubMed Web of Science ®Google Scholar
• LA MARCA A, EGBE TO, MORGANTE G et al.: Metformin treatment reduces ovarian cytochrome P450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Hum. Reprod. (2000) 15:21–23.
   PubMed Web of Science ®Google Scholar
• NESTLER JE, JAKUBOWICZ DJ: Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl. Med (1996) 335:617–623.
   PubMed Web of Science ®Google Scholar
• ••Seminal study of pathophysiology ofinsulin resistance in PCOS.
   Google Scholar
• NESTLER JE, JAKUBOWICZ DJ: Leanwomen with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. Clin. Endocrine] Metab. (1997) 82:4075–4079.
   PubMed Web of Science ®Google Scholar
• NESTLERJE, JAKUBOWICZ DJ, EVANS WS, PASQUALI R: Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl. I Med. (1998) 338:1876–1880.
   PubMedGoogle Scholar
• ••Effectiveness of metformin with andwithout domiphene in PCOS.
   Google Scholar
• NESTLERJE: Obesity, sex steroids, and ovulation. Int..). of Obesity (2000) 14\(Suppl. 2):571–573.
   Google Scholar
• VRBIKOVA J, HILL M, STARKA L et al.: The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome. Eur: Endocrine] (2001) 144:619–628.
   PubMed Web of Science ®Google Scholar
• VRBIKOVA J, HILL M, STARKA L et al.: Effect of long-term treatment with metformin on steroid levels and parameters of insulin resistance in women with polycystic ovary syndrome. Cas. Lek. Cesk (2001) 140:688–694.
   PubMedGoogle Scholar
• AZZIZ R, EHRMANN E, LEGRO RS et al.: Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double-blind, placebo-controlled trial. I Clin. Endocrine] Metab. (2001) 86:1626–1632.
   PubMed Web of Science ®Google Scholar
• ••Large, placebo-controlled, blind study oftroglitazone in PCOS.
   Google Scholar
• IUORNO MJ, NESTLER JE: Insulin-lowering drugs in polycystic ovary syndrome. Ob. Gyn. Clin. N Am. (2001) 28:153–164.
   PubMed Web of Science ®Google Scholar
• CATALDO NA, ABBASI F, MCLAUGHLIN TL, LAMENDOLA C, REAVEN GM: Improvement in insulin sensitivity followed by ovulation and pregnancy in a woman with polycystic ovary syndrome who was treated with rosiglitazone. Fenn. Sterul. (2001) 76:1057–1059.
   PubMed Web of Science ®Google Scholar
• NESTLERJE, JAKUBOWICZ DJ, REAVER P, GUNN RD, ALLAN G: Ovulatory and metabolic effects of d-chiro-inositol in the polycystic ovary syndrome. NEng.j Med. (1999) 340:1314–1320.
   PubMed Web of Science ®Google Scholar
• ••Seminal study on usefulness of D-chiroinositol in PC OS.
   Google Scholar
• MIT WALLY ME KUSEU NK, YALEINKAYA TM: High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome. Hum. Reprod. (1999) 14:2700–2703.
   PubMedGoogle Scholar
• GLUECK CJ, WANG P, SIEVE-SMITH L, GOLDENBERG N: Pre-pregnancy lowering of insulin, glucose, insulin resistance, and weight by metformin is maintained through pregnancy in women with polycystic ovary syndrome. J. Invest. Med. (2002) 50:172A. Abstract.
   Google Scholar
• JAKUBOWICZ DJ, IUORNO MJ, JAKUBOWICZ S et al.: Effects of metformin on early pregnancy, loss in the polycystic ovary syndrome. J. Clin. Endocrinol Metab (2002) 87:524–529.
   PubMed Web of Science ®Google Scholar
• ••Second study confirming safety andefficacy of metformin in reduction of first trimester spontaneous abortion in PCOS and lack of teratogenicity.
   Google Scholar
• GJONNAESS H: Ovarian electrocautery in the treatment of women with polycystic ovary syndrome (PCOS). Factors affecting the results. Acta Obstet. Gynecol Scand. (1994) 73:407–412.
   PubMed Web of Science ®Google Scholar
• ••Effectiveness of ovarian electrocautery inameliorating reproductive morbidity in PCOS.
   Google Scholar
• DAHLGREN E, JOHANSSON S, LINDSTEDT G et al.: Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones. Feral. Sterd. (1992) 57:505–513.
   PubMed Web of Science ®Google Scholar
• •Natural history of ovarian wedge resection.
   Google Scholar
• VANDERMOLEN DT, RATTS VS, EVANS WS, STOVALL DW, KAUMA SW, NESTLER JE: Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Ferti/. Stern. (2001) 75:310–315.
   PubMed Web of Science ®Google Scholar
• BATUKAN C, BAYSAL B: Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syndrome. Arch. Gynecol Obstet. (2001) 265:124–127.
   PubMedGoogle Scholar
• PARSANEZHAD ME, ALBORZI S, ZAREI A, DEHBASHI S, OMRANI G: Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin. hat. ". Gynaecol Obstet. (2001) 75:43–50.
   Google Scholar
• STADTMAUER LA, TOMA SK, RIEHL RM, TALBERT LM: Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Feral. Steril (2001) 75:505–509.
   PubMed Web of Science ®Google Scholar
• ••Importance of metformin in facilitating IVF in women with PCOS.
   Google Scholar
• ACBAY O, GUNDOGDU S: Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Stern. (1996) 65:946–949.
   Google Scholar
• EHRMANN DA, CAVAGHAN MK, IMPERIAL J et al.: Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome." Clin. Endocrinol Metab. (1997) 82:524–530.
   Google Scholar
• DIAMANTI-KANDARAKIS E, KOULI C, ISIANATELI T, BERGIELE A: Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur. Endocrinol (1998) 138:269–274.
   PubMed Web of Science ®Google Scholar
• DIAMANTI-KANDARAKIS E, SPINA G, KOULI C, MIGDALIS I: Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J. Clin. Endocrinol Metab. (2001) 86:4666–4673.
   PubMed Web of Science ®Google Scholar
• IBANEZ L, VALLS C, FERRER A, MARCOS MV, RODRIGUEZ-HIERRO F, DE ZEGHER F: Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. Clin. Endocrinol Metab. (2001) 86:3595–3598.
   Google Scholar
• IBANEZ L, VALLS C, POTAU N, MARC OS MV, DE ZEGHER F: Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. Clin. Endocrinol Metab. (2000) 85:3526–3532.
   Google Scholar
• •Insulin sensitivity in adolescent girls.
   Google Scholar
• KOCAK M, CALISKAN E, SIMSIR C, HABERAL A: Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertil. Steril (2002) 77:101–106.
   PubMed Web of Science ®Google Scholar
• MOGHETTI P, CASTELLO R, NEGRI C et al: Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. Clin. Endocrinol Metab. (2000) 85:139–146.
   Google Scholar
• MORIN-PAPUNEN LC, KOIVUNEN RM, RUOKONEN A, MARTIKAINEN HK: Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Feral. Sterd. (1998) 69:691–696.
   PubMed Web of Science ®Google Scholar
• MORIN-PAPUNEN LC, VAUHKONEN I, KOIVUNEN RM, RUOKONEN A, MARTIKAINEN HK, TAPANAINEN JS: Endocrine and metabolic effects of metformin versus ethinylestradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. I Clin. Endocrinol Metab. (2000) 85:3161–3168.
   PubMed Web of Science ®Google Scholar
• NG EH, WAT NM, HO PC: Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Hum. Reprod. (2001) 16:1625–1631.
   PubMed Web of Science ®Google Scholar
• PASQUALI R, GAMBINERI A, BISCOTTI D et al.: Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Clin. Endocrinol Metab. (2000) 85:2767–2774.
   Google Scholar
• NESTLERJE, STOVALL D, AKHTER N,IUORNO MJ, JAKUBOWICZ DJ: Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Feral. Sterd. (2002) 77:209–215.
   PubMed Web of Science ®Google Scholar
• •Seminal review.
   Google Scholar
• EHRMANN DA, SCHNEIDER DJ, SOBEL BE et al.: Troglitazone improves defects in insulin action, insulin secretion, ovarian steriodogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol Metab. (1997) 82:2108–2116.
   PubMed Web of Science ®Google Scholar
• PARULKAR AA, PENDERGRSS ML, GRANDA-AYALA R, LEE TR, FONSECA VA: Nonhypoglycemic effects of thiazolidinedioness. Ann. Int. Med. (2002)134:61–71.
   Google Scholar
• NESTLER JE, JAKUBOWICZ DJ, IUORNO MJ: Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome. J. Ped. Endo. (2000) 13\(Suppl. 5):1295–1298.
   Google Scholar
• NESTLER JE, JAKUBOWICZ DJ, REAMER P, GUNN RD, ALLAN G: Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl. J. Med. (1999) 340:1314–1320.
   PubMed Web of Science ®Google Scholar
• •• Innovative approach to insulin sensitisation with D-chiro-inositol.
   Google Scholar
• LARNER J, ALLAN G, KESSLER C, REAMER P, GUNN R, HUANG LD: Phosphoinositol glycan derived mediators and insulin resistance. Prospects for diagnosis and therapy. I Basic Clin. Physic] Pharmacol (1998) 9:127–137.
   Google Scholar
• ••Biochemistry of inositolphosphoglycanmediators.
   Google Scholar
• CAMPBELL WW, OSTLUND RE JR JOSEPH LJ, FARRELL PA, EVANS WJ: Relationships of plasma C-peptide and gender to the urinary excretion of inositols in older groups. Harm. Metab. Res. (2001) 33:44–51.
   PubMed Web of Science ®Google Scholar
• LARNER J: D-chiro-inositol - its functional role in insulin action and its deficit in insulin resistance. Int. J. Exp. Diabetes Res. (2002) 3:47–60.
   PubMedGoogle Scholar
• ••Seminal paper on D-chiro-inositol and itsrole in insulin resistance.
   Google Scholar
• GLUECK CJ, SIEVE-SMITH L, GOLDENBERG N et al.: Normal growth in the first year of life in 154 infants with gestation 37 weeks and whose mothers with polycystic ovary syndrome conceived on and took metformin during pregnancy. J. Invest. Med. (2002) 50:172A. Abstract.
   Google Scholar
• COETZEE EJ, JACKSON WP: The management of non-insulin-dependent diabetes during pregnancy. Diabetes Res. Clin. Pract. (1985-1986) 1:281–287.
   Google Scholar
• COETZEE EJ, JACKSON WP: Oral hypoglycaemics in the first trimester and fetal outcome. S. Air. Med. J. (1984) 65:635–637.
   PubMed Web of Science ®Google Scholar
• COETZEE EJ, JACKSON WP: Pregnancy in established non-insulin-dependent diabetics. A five-and-a-half year study at Grote Schuur Hospital. S. Air. Med..]: (1980) 58:795–802.
   Google Scholar
• COETZEE EJ, JACKSON WP: Metformin in management of pregnant insulin-dependent diabetics. Diabetalogia (1979) 16:241–245.
   PubMed Web of Science ®Google Scholar
• JACKSON WP, COETZEE EJ: Side-effects of metformin. S. Ali: Med. J. (1979) 56:1113–1114.
   PubMedGoogle Scholar
• HEARD MJ, PIERCE A, CARSON SA, BUSTER JE: Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. Fern]. Stern. (2002) 77:669–673
   PubMed Web of Science ®Google Scholar
• •Metformin for ovulation induction and conception.
   Google Scholar
• DENNO KM, SADLER TW: Effects of the biguanide class of oral hypoglycemic agents on mouse embryogenesis. Teratology (1994) 49:260–266.
   PubMedGoogle Scholar
• GLUECK CJ, PHILLIPS H, CAMERON Det al: The 4G/4G polymorphism of the hypofibrinolytic plasminogen activator inhibitor Type 1 gene: an independent risk factor for serious pregnancy complications. Metabolism (2000) 49:845–852.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, KUPFERMINC MJ, FONTAINE RN, WANG P, WEKSLER BB, ELDOR A: Genetic hypofibrinolysis in complicated pregnancies. Obstet. Gynecol (2001) 97:44–48.
   PubMed Web of Science ®Google Scholar
• JAKUBOWICZ DJ, SEPPALA M, JAKUBOWICZ S et al.: Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J. Clin. Endocrinol Metab. (2001) 86:1126–1133.
   PubMed Web of Science ®Google Scholar
• KOUSTA E, CELA E, LAWRENCE N et al.: The prevalence of polycystic ovaries in women with a history of gestational diabetes. Clin. Endocrinol (2000) 53:501–507.
   PubMedGoogle Scholar
• KOWALSKA I, KINALSKI M, STRACZKOWSKI M, WOLCZYSKI S, KINALSKA I: Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome. Eur. Endocrinol (2001) 144:509–515.
   PubMed Web of Science ®Google Scholar
• LEGRO RS, KUNSELMAN AR, DODSON WC, DUNAIF A: Prevalence and predictors of risk for Type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women." Clin. Endocrinol Metab. (1999) 84:165–169.
   PubMed Web of Science ®Google Scholar
• NARDO LG, RAI R: Metformin therapy inthe management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects. Gynecol Endocrinol (2001) 15:373–380.
   PubMed Web of Science ®Google Scholar
• NORMAN RJ, MASTERS L, MILNER CR, WANG JX, DAVIES MJ: Relative risk of conversion from normoglycemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Human Reprod. (2000) 16:1995–1998.
   Google Scholar
• EHRMANN DA, BARNES RB, ROSENFIELD RL et al.: Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care (1999) 22:141–146.
   PubMed Web of Science ®Google Scholar
• KORHONEN S, HIPPELAINEN M, NISKANEN L, VANHALA M, SAARIKOSKI S: Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study. Amer. I. Ob. Gyn. (2001) 184:289–296.
   PubMed Web of Science ®Google Scholar
• CONN JJ, JACOBS HS, CONWAY GS: The prevelance of polycystic ovaries in women with Type 2 diabetes mellitus. Clin. Endo. (2000) 52:81–86.
   PubMed Web of Science ®Google Scholar
• PEPPARD HR, MARFORI J, NESTLER JE: Prevalence of polycystic ovary syndrome among premenopausal women with Type 2 diabetes. Diabetes Care (2001) 24:1050–1052.
   PubMed Web of Science ®Google Scholar
• SOLOMON CG, HU FB, DUNAIF A et al.: Long or highly irregular menstrual cycles as a marker for risk of Type 2 diabetes mellitus. JAMA (2001) 286:2421–2426.
   PubMed Web of Science ®Google Scholar
• HU FB, MANSON JE, STAMPFER MJ et al.: Diet, lifestyle, and the risk of Type 2 diabetes mellitus in women. N Engl. Med. (2001) 345:790–797.
   PubMed Web of Science ®Google Scholar
• LILLIOJA S, MOTT DM, SPRAUL M et al.: Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl. I Med. (1993) 329:1988–1992.
   PubMed Web of Science ®Google Scholar
• POLDERMAN KH, GOOREN LJ, ASSCHEMAN H, BAKKER A, HEINE RJ: Induction of insulin resistance by androgens and estrogens. J. Clin. Endocrinol Metabol (1994) 79:265–271.
   PubMed Web of Science ®Google Scholar
• BUTTE NF: Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. Am. J. Clin. Nutr. (2000) 71 (Suppl.):1256S–1261S.
   Google Scholar
• XIANG AH, PETERS RK, TRIGO E, KJOS SL, LEE WP, BUCHANAN TA: Multiple metabolic defects during late pregnancy in women at high risk for Type 2 diabetes. Diabetes (1999) 48:848–854.
   PubMed Web of Science ®Google Scholar
• BUCHANAN TA, XIANG AH, PETERS RK et al.: Response of pancreatic beta cells to improved insulin sensitivity in women at high risk for Type 2 diabetes. Diabetes (2000) 49:782–788.
   PubMed Web of Science ®Google Scholar
• DIABETES PREVENTION PROGRAM RESEARCH GROUP: Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N Engl. J. Med. (2002) 346:393–403.
   PubMed Web of Science ®Google Scholar
• ••Innovative approach to primary preventionof Type 2 diabetes.
   Google Scholar
• HOD M, BAR J, PELED Y: Antepartummanagement protocol: timing and mode of delivery in women with gestational diabetes. Diabetes Care (1998) 21\(Suppl. 2):B113–B117.
   Google Scholar
• PERSSON B, HANSON U: Neonatal morbidities in gestational diabetes mellitus. Diabetes Care (1998) 21 (Suppl. 2):B79–B84.
   Google Scholar
• HELLMUTH E, DAMM P, MOLSTED-PEDERSEN L: Oral hypoglycemic agents in 118 diabetic pregnancies. Diabet. Med. (2000) 17:507–511.
   PubMed Web of Science ®Google Scholar
• JONES CN, ABBASI F, CARANTONI M, POLONSKY KS, REAVEN GM: Roles of insulin resistance and obesity in regulation of plasma insulin concentrations. Physic] Endocrinol Metab. (2000) 278:E501–E508.
   Google Scholar
• LU GC, ROUSE DJ, DUBARD M, CLIVER S, KIMBERLIN D, HAUTH JC: The effect of the increasing prevelance of maternal obesity on perinatal morbidity. Ain. J. Obstet. Gynecol (2001) 185:845–849.
   PubMed Web of Science ®Google Scholar
• MORIN-PAPUNEN LC, KOIVUNEN RM, TOMAS C, RUOKONEN A, MARTIKAINEN HK: Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. J. Clin. Endocrinol Metabol (1998) 83:2566–2568.
   PubMed Web of Science ®Google Scholar
• FREEMARK M, BURSEY D: The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of Type 2 diabetes. Pediatrics (2001) 107:E55.
   PubMed Web of Science ®Google Scholar
• ••Primary prevention of Type 2 diabetes.
   Google Scholar
• GLUECK CJ, FONTAINE RN, WANG P et al: Metformin reduces weight centripetal obesity, insulin, leptin, and low density lipoprotein cholesterol in nondiabetic, morbidly obese subjects with body mass index greater than 30. Metabolism (2001) 50:856–861.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, WANG P, GARTSIDE PS et al.: Progression of morbid obesity in women with polycystic ovary syndrome and amelioration with metformin. Invest. Med. (2001) 49:201A. Abstract.
   Google Scholar
• JOFFE B, ZIMMET P: The thrifty genotype in Type 2 diabetes: an unfinished symphony moving to its finale? Endocrine (1998) 9:139–141.
   PubMedGoogle Scholar
• BIRNBAUM M.J: Diabetes: dialogue between muscle and fat. Nature (2001) 409:672–673.
   PubMedGoogle Scholar
• ZARATE A, HERNANDEZ M, FONSECA ME, OCHOA R: Use of metformin in the management of adolescents with polycystic ovary syndrome. Ginecol Obstet. Mex. (1997) 65:504–507.
   PubMedGoogle Scholar
• CAREY AH, CHAN KL, SHORT F, WHITE D, WILLIAMSON R, FRANKS S: Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin. Endocrinol (Oxford) (1993) 38:653–658.
   PubMed Web of Science ®Google Scholar
• ••Genotypic and phenotypic manifestationsof PC OS in men and women.
   Google Scholar
• GOVIND A, OBHRAI MS, CLAYTON RN: Polycystic ovaries are inherited as an autosomal dominant trait: analysis of 29 polycystic ovary syndrome and 10 control families. Clin. Endocrinol Metab. (1999) 84:38–43.
   Google Scholar
• KASHAR-MILLER M, AZZIZ R: Heritability and the risk of developing androgen excess. J. Steroid Biochein. MM. Biol. (1999) 69:261–268.
   PubMed Web of Science ®Google Scholar
• URBANEK M, LEGRO RS, DRISCOLL D, STRAUSS JF, DUNAIF A, SPIELMAN RS: Searching for the polycystic ovary syndrome genes. J. Pediati: Endocrinol Metabolism. (2000) 13 (Suppl.):1311–1313.
   Google Scholar
• CRAVE JC, FIMBEL S, LEJUENE H, CUGNARDEY N, DECHAUD H, PUGEAT M: Effects of diet and metformin administration on sex-hormone binding globulin, androgens, and insulin in hirsute and obese women. Clin. Endocrinol Metab. (1995) 80:2057–2062.
   Google Scholar
• GRUNDY SM: Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am. J. Cardiol (1999) 83:25F–29F.
   Google Scholar
• FORD ES, GILES WH, DIETZ WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA (2002) 287:356–359.
   PubMed Web of Science ®Google Scholar
• ••PCOS is synonymous for the metabolicsyndrome.
   Google Scholar
• FACCHINI FS, HUA N, ABBASI F et al.: Insulin resistance as a predictor of age-related diseases. J. Clin. Endo. Metabol (2001) 86:3574–3578.
   PubMed Web of Science ®Google Scholar
• GLUECK CJ, LANG JE, TRACY T, SIEVE-SMITH L, WANG P: Contribution of fasting hyperinsulinemia to prediction of atherosclerotic cardiovascular disease status in 293 hyperlipidemic patients. Metabolism (1999) 48:1437–1444.
   PubMedGoogle Scholar
• TALBOTT E, GUZICK K, CLERICI A et al.: Coronary heart disease risk factors in women with polycystic ovary syndrome. Arteriosc/e. Thrornb. Vase. Biol. (1995) 15:821–826.
   PubMed Web of Science ®Google Scholar
• TALBOTT EO, ZBOROWSKI JV, SUTTON-TYRRELL K, MCHUGH-PEMU KP, GUZICK DS: Cardiovascular risk in women with polycystic ovary syndrome. Ob. Gyn. Clin. N Am. (2001) 28:111–133.
   PubMed Web of Science ®Google Scholar
• LOUCKS T, TALBOTT ED, MCHUGH KP, KEELAN M, BERGA SL, GUZICK DS: Do polycystic ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome? Fert. Sterd. (2000) 74:547–552.
   PubMed Web of Science ®Google Scholar
• PARADISI G, STEINBERG HO, HEMPFLING A et al.: Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation. (2001) 103:1410–1415.
   PubMed Web of Science ®Google Scholar
• YARALI H, YILDIRIR A, AYBAR F et al.: Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome. Feral. Steil]. (2001) 76:511–516.
   PubMed Web of Science ®Google Scholar
• GUZICK DS, TALBOTT EO, SUTTON-TYRELL K, HERZOG HC, KULLER LH, WOLFSON SK Jr: Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am. Obstet. Gynecol (1996) 174:1224–1229.
   PubMed Web of Science ®Google Scholar
• BIRDSALL MA, FARQUHAR CM, WHITE HD: Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Am..). Glister Gynecol (1997) 126:32–35.
   Google Scholar
• DAHLGREN E, JANSON PO, JOHANSSON S, LAPIDUS L, ODEN A: Polycystic ovary syndrome and risk for myocardial infarction: evaluated from a risk factor model based on a prospective population study of women. Acta. Glister Gynecol Scand. (1992b) 71:559–604.
   Google Scholar
• DIAMANTI-KANDARAKIS E, ZAPANTI E: Insulin sensitizers and antiandrogens in the treatment of polycystic ovary syndrome. Ann. NY Acad. Sci. (2000) 900:203–212.
   PubMed Web of Science ®Google Scholar
• DIAMANTI-KANDARAKIS E, MITRAKOU A, HENNES MM et al: Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. Metabolism (1995) 44:525–531.
   PubMed Web of Science ®Google Scholar
• PAOLETTI AM, CAGNACCI A, ORRU M, AJOSSA S, GUERRIERO S, MELTS GB: Treatment with flutamide improves hyperinsulinemia in women with idiopathic hirsutism. Fertil. Sten]. (1999) 72:448–453.
   PubMed Web of Science ®Google Scholar
• DIAMANTI-KANDARAKIS E, MITRAKOU A, RAPTIS S, TOLIS G, DULEBA AJ: The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in polycystic ovary syndrome. j. Clin. Endocrine]. Metab (1998) 83:2699–2705.
   PubMed Web of Science ®Google Scholar
• IBANEZ 1, POTAU N, MARCOS MV, DE ZEGHER F: Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in non-obese, adolescent girls: effect of flutamide. Clin. Endocrine]. Metab. (2000) 85:3251–3255.
   PubMedGoogle Scholar
• MOGHETTI P, TOSI F, CASTELLO R et al.: The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. Clin. Endocrine]. Metab. (1996) 81:952–960.
   PubMed Web of Science ®Google Scholar
• FALSETTI L, GAMBERA A, TISI G: Efficacy of the combination ethyinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovary syndrome. Hum. Reprod. (2001) 16:36–42.
   PubMed Web of Science ®Google Scholar
• ARMSTRONG VL, WIGGAM MI, ENNIS CN et al.: Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/ cyproterone acetate. QIM (2001) 94:31–37.
   PubMedGoogle Scholar
• MORIN-PAPUNEN LC, VAUHKONEN I, KOIVUNEN PM, RUOKONEN A, MARTIKAINEN HK, TAPANAINEN JS: Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J. Clin. Endocrine]. Metabol (2000) 85:3161–3165.
   PubMed Web of Science ®Google Scholar
• DAHLGREN E, LANDIN K, KROTKIEWSKI M, HOLM G, JANSON PO: Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome. Hum. Reprod. (1998) 13:2706–2711.
   PubMed Web of Science ®Google Scholar
• MASTORAKOS G, KOLIOPOULOS C, CREATSAS G: Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined contraceptives. Feral. Sterd. (2002) 77:919–927.
   PubMed Web of Science ®Google Scholar
• ODLING V, MILSOM I, PERSSON I, VICTOR A: Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet. Cynecol Scand. (2002) 81:482–490.
   PubMedGoogle Scholar
• CARMINA E: Anti-androgens for the treatment of hirsutism Expert Opin. Investig. Drugs (2002) 11 (3):357–363.
   Google Scholar
• •An excellent, comprehensive review.
   Google Scholar
• GODSLAND IF, WALTON C, FELTON C, PROUDLER A, PATEL A, WYNN V: Insulin resistance, secretion, and metabolism in users of oral contraceptives. Clin. Endocrine]. Metab. (1992) 74:64–70.
   PubMed Web of Science ®Google Scholar
• SILLS ES, PERLOE M, PALERMO GD: Correction of hyperinsulinemia in oligoovulatory women with clomiphene-resistant polycystic ovary syndrome: a review of therapeutic rationale and reproductive outcomes. Eur. Obstet. Cynecol Reprod. Biel (2000) 91:135–141.
   PubMedGoogle Scholar
• RYAN KJ, SMITH OW: Biogenesis of steroid hormones in the human ovary. Recent Prog. Herm. Res (1965) 21:367–388.
   PubMedGoogle Scholar
• IBANEZ L, HALL JE, POTAU N, CARRASCOSA A, PRAT N, TAYLOR AE: Ovarian 17-hydroxyprogesterone hyperresponsiveness to gonadotropin-releasing hormone (GnRH) agonist challenge in women with polycystic ovary syndrome is not mediated by lutenizing hormone hypersecretion: evidence from GnRH agonist and human chorionic gonadotropin stimulation testing. I Clin. Endocrine]. Metab. (1996) 81:4103–4107.
   PubMed Web of Science ®Google Scholar
• FULGHESU AM, VILLA P, PAVONE Vet al.: The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome. I Clin. Endocrine]. Metab. (1997) 82:644–648.
   Google Scholar